Pandemic Influenza Vaccine Policy — Considering the Early Evidence
- 17 December 2009
- journal article
- editorial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 361 (25) , e59
- https://doi.org/10.1056/nejme0908224
Abstract
“Policy decisions regarding influenza rest on judgments about the behavior of the virus, the impact of the disease and our ability to interdict its course. But the virus is capricious, the disease elusive, and our remedies imperfect,” said a report on the 1976 swine-flu epidemic at Fort Dix.1Keywords
This publication has 6 references indexed in Scilit:
- Trial of 2009 Influenza A (H1N1) Monovalent MF59-Adjuvanted VaccineNew England Journal of Medicine, 2009
- Response to a Monovalent 2009 Influenza A (H1N1) VaccineNew England Journal of Medicine, 2009
- Poverty, Wealth, and Access to Pandemic Influenza VaccinesNew England Journal of Medicine, 2009
- Half- vs Full-Dose Trivalent Inactivated Influenza Vaccine (2004-2005)Archives of internal medicine (1960), 2008
- Evaluation of a single dose of half strength inactivated influenza vaccine in healthy adultsVaccine, 2002
- Guillain-Barré Syndrome and the 1978–1979 Influenza VaccineNew England Journal of Medicine, 1981